IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas...
IL-15 superagonistLeukemiaN-803Natural killer cellOvarian cancerAllogeneic natural killer (NK) cell transfer is a potential immunotherapy to eliminate and control cancer. A promising source are CD34 + hematopoietic progenitor cells (HPCs), since large numbers of cytotoxic NK cells can be generated. ...
2022年1月31日,美国明尼苏达大学医学院的研究人员在国际顶尖医学期刊Nature Medicine上发表了题为:Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial的1期临床试验论文。 该1期临床试验...
1.FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer | FDA 2.Novel IL-15 superagonist N-803 hits high complete response rate in BCG-unresponsive NMIBC (urologytimes.com)3.IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladde...
An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC) (Journal of Thoracic Oncology; IF: 20.121) Fousek K, Horn LA, Qin H, Dahut M, Iida M, Yacubovich D, Hamilton DH, homas A, Schlom J, Palena C, An IL-15 ...
3.IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer | NEJM Evidence 4.ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - ImmunityBio, Inc....
2022年1月31日,美国明尼苏达大学医学院的研究人员在国际顶尖医学期刊Nature Medicine上发表了题为:Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial的1期临床试验论文。 该1期临床试验验证了新型免疫治疗药——IL-15超级激动剂N-803在治疗艾滋病方面的...
[1] ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients, May 5, 2021, from https://www.businesswire.com/news/home/20210504005511/en ...
[1] ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients, May 5, 2021, from https://www.businesswire.com/news/home/20210504005511/en ...
ALT-803是一种专有的、新型IL-15“超级激动剂(superagonist)”复合物;在临床前研究中,与IL-15相比,ALT-803具有改善的药代动力学特性和增强的抗肿瘤活性。这些研究还表明,针对癌细胞和感染病毒的细胞,ALT-803能同时调动免疫系统的先天免疫和适应性免疫,激发迅速、强大、持久的免疫反应。此外,在各种实验动物模型中,...